The Power of Vaccines: ‘getting to zero’ for HIV and TB was an event hosted by the TB/HIV and Prevention Working Groups of the UK Consortium on AIDS and International Development. The meeting was sponsored by Pamela Nash MP and held on Friday, 18th May 2012, in Portcullis House, Westminster. Read more at http://storify.com/PamojaUK/the-power-of-vaccines http://www.pamoja.uk.com

1. The Power of Vaccines:
‘getting to zero’ for HIV and TB
Understanding the R&D funding
landscape
Roni Liyanage
Senior Policy Analyst
rliyanage@policycures.org

2. Outline
• About Policy Cures
• About G-FINDER
• Neglected disease R&D funding
• Vaccine R&D funding
• HIV & TB vaccine funding
• Key messages

3. About Policy Cures
Innovative ideas and
accurate analysis to
accelerate development
and uptake of new drugs,
vaccines, diagnostics and
other products for
neglected diseases of the
developing world

4. About G-FINDER
• An annual funding survey (2007, 2008, 2009,
2010)
– 31 neglected diseases
– 134 product areas
– All R&D stages
• Over 8,000 entries per year
– Data from 54 countries <INSERT PICTURE>
– Data from 240 organisations
• Funded by the Bill & Melinda Gates
Foundation
WHO/MALI

5. Neglected Disease R&D Funding

6. Total Neglected Disease R&D funding
$3,500
Millions
$3,000
$2,500
$3,063
$2,000
million
$1,500 invested in neglected
disease R&D in 2010
$1,000
$500
↓$109m (-3.5%)
$0
2007 2008 2009 2010

7. HIV & TB R&D funding
$1,200
Millions
HIV/AIDS TB
$1,000
$800
$600 HIV
$1.07 TB $575.4
BILLION $400
MILLION
Total spend on Total spend on TB R&D
HIV/AIDS R&D in 2010 in 2010
$200
35% 18.8%
of Global ND R&D $- of Global ND R&D
funding 2007 2008 2009 2010 funding

8. Vaccine R&D Funding

9. Vaccine R&D funding
$1,400
Millions
$1,200 62%
Public funding
$1,000
$800
$600
20%
$400 Industry funding
$200
$0
2007 2008 2009 2010
17%
Public funding Industry funding Philanthropic funding Philanthropic funding

10. Vaccine R&D funding
Bacterial
Other 4% Pneumonia &
Meningitis 7%
Diarrhoeal
diseases 7%
Malaria 8%
HIV/AIDS
55%
TB 9%
Dengue 10%

11. Top funders of neglected disease vaccine R&D, 2010
1 NIH $509m
2 Pharmaceutical Industry $223m
3 Bill & Melinda Gates Foundation $176m
4 US Department of Defense (DOD) $43m
5 US Agency for International Development (USAID) $33m
6 UK Department for International Development (DFID) $30m
7 European Commission: Research Directorate-General $27m

12. HIV & TB Vaccine R&D Funding

13. HIV & TB Vaccine R&D funding 2007-2010
$700
Millions
HIV/AIDS TB
$600
$500
$400
HIV
$589.9 $300 TB $81.9
million $200 MILLION
Total spend on HIV Total spend on TB
Vaccine R&D in 2010 $100 Vaccine R&D in 2010
$-
2007 2008 2009 2010

14. HIV Vaccine R&D funding – by funder type 2010
Industry
Philanthropic funding
funding 2% Top funders HIV Vaccine R&D, 2010
12% 1 US NIH $414m
2 Bill & Melinda Gates $65m
Foundation
3 USAID $27m
4 US DoD $25m
5 Industry $21m
6 UK DFID $14m
Public 7 European Commission $10m
funding
86% 8 The Wellcome Trust $4m

15. TB Vaccine R&D funding – by funder type, 2010
Other
Industry
2% Top funders TB Vaccine R&D, 2010
funding 1 Bill & Melinda Gates Foundation $30m
9% Public funding
49% 2 Industry $17m
3 US NIH $15m
4 UK DFID $10m
5 Health Protection Agency $4m
6 European Commission $4m
Philanthropic
funding
40%

16. Science & Technology Vs Aid funding
90% of public funding for HIV vaccine R&D came from
Science and Technology funding agencies in 2010
66% of public funding for TB vaccine R&D came from
Science and Technology funding agencies in 2010

17. European public funding of HIV Vaccine R&D
$70
Millions
$60 ↓$15.8m (-29%) in 2010
Norway
$50 Switzerland
France
$40
Sweden
Denmark $16.7m (-22%) in 2010
$30 From UK
Ireland
Netherlands
$20
European Commission
UK
$10
$10.8m (-36%) in 2010
$-
From EC
2007 2008 2009 2010

18. European public funding of TB Vaccine R&D
$35
Millions
$30 ↓$5.9m (-20%) in 2010
$25 Spain
Sweden
$20
Denmark
Switzerland $14.3m (up 21%) in 2010
$15 From UK
Netherlands
European Commission
$10
UK
$5
$4.0m (-45%) in 2010
From EC
$-
2007 2008 2009 2010

19. The HIV and TB vaccine portfolios
30
25
20
Preclinical Several products moving
15 Phase I into expensive late-stage
Phase II clinical trials
10
Phase III
5
0
HIV Vaccines TB Vaccine

20. Key messages

21. Vaccine R&D funding for neglected diseases
• Funding is highly concentrated
• Mostly comes from:
• US funders
• Public sector
• Science and technology budgets
• Funding cuts at a time when several
promising products are entering late
stage development

22. Vaccine R&D funding for neglected diseases
- R&D pipelines need reliable long-term funding
- Financial pressures mean smarter funding will be needed:
- Outcome driven and flexible
- Aligned with product and portfolio developments
- Coordinated
- Targeted to deliver the highest health impact

23. It took a long time and a lot of effort to restart
neglected disease vaccine R&D but it is under
threat –
The time to act is NOW